New genomics division
Diagnostic and analytical testing services provider LGC has announced the launch of a new genomics division.
Diagnostic and analytical testing services provider LGC has announced the launch of a new genomics division. According to the company it has been seeing successful growth in the area of genomics as part of the company’s Life and Food Sciences division since the 2005 acquisition of AGOWA. Through the acquired genomics company, LGC has provided an array of flexible nucleic acid sample extraction services and products, DNA sequencing, next generation sequencing and genomic services to international pharmaceutical and biotechnology companies and private and public research organizations.
“The launch of LGC Genomics as a new operating division is an exciting step for LGC and presents excellent opportunities for growth,” said John McQuillian, managing director of the new division, in a statement. “Under the new brand, LGC Genomics will continue to advance the development and delivery of first-rate genomic services and products, keeping our customers at the forefront of technology and expertise in this increasingly sophisticated field of science.”
As part of the restructuring process, AGOWA genomics products and services will be rebranded LGC Genomics. For more information visit www.lgc.co.uk
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
